Cookie Law

Nashiyat uebsaĭt izpolzva biskvitki, nyakoi ot koito sa ot sŭshtestveno znachenie za pravilnoto funktsionirane na tozi saĭt i veche sa zadadeni. Za poveche informatsiya otnosno upravlenieto, blokiraneto ili iztrivaneto na „biskvitki“ v brauzŭra vi, molya, vizhte prepratkite v nashata Politika za poveritelnost. Chrez izpolzvaneto na nashiya saĭt priemate usloviyata na nashata Politika za poveritelnost.

Funktsionalni biskvitki

Funktsionalnite biskvitki sa ot sŭshtestveno znachenie za pravilnoto funktsionirane na uebsaĭta. Tezi „biskvitki“ ne sŭbirat nikakvi lichni danni.

View details

Statistika na uebsaĭta

Pozvolete ni da sŭbirame anonimni statisticheski danni za tova kak se izpolzva uebsaĭtŭt. Sŭbranite po tozi nachin danni se obobshtavat s tsel analizirane na tendentsiite v izpolzvaneto na uebsaĭta.

View details

Youtube / Vimeo videoklipove

Videoklipovete na tozi uebsaĭt se predostavyat ot platformata na YouTube za potochno predavane. YouTube mozhe da pokazva personalizirani reklami predi pokazvaneto na videoklipa. Tova razreshenie e po izbor, no e neobkhodimo da gledate videoklipovete direktno na tozi uebsaĭt.

View details

Zabravete nastroĭkite mi Deleted!

Summary of Indications for Use
DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling, or at www.durolane.com.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Galderma S.A.

© 2019 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.